Illumina, Inc. (ILMN) Q3 2025 Earnings Call Transcript

Illumina (ILMN) reported strong Q3 2025 results, exceeding guidance with $1.08 billion in revenue (flat year-over-year, +2% ex-China), 24.5% non-GAAP operating margin, and $1.34 non-GAAP diluted EPS, primarily driven by robust clinical market demand and the accelerated NovaSeq X transition. The company surpassed its year-end goals for NovaSeq X adoption, with 75% of high-throughput gigabases and 50% of high-throughput revenue now on the X platform, while also advancing multiomics offerings and the BioInsight initiative. Consequently, Illumina raised its full-year 2025 revenue and non-GAAP EPS guidance, anticipating continued clinical strength and easing research pricing headwinds into 2026, reinforcing its long-term targets of high single-digit revenue growth and 20% non-GAAP operating margins by 2027.

Analysis

Illumina (ILMN) reported a strong Q3 2025, exceeding guidance with $1.08 billion in revenue, a 24.5% non-GAAP operating margin, and $1.34 non-GAAP diluted EPS, representing 18% year-over-year growth. This performance was primarily fueled by robust demand in the clinical market, which achieved double-digit revenue growth outside China, and the accelerated adoption of the NovaSeq X platform. The company also demonstrated financial strength with $284 million in cash flow from operations and $120 million in share repurchases.

The NovaSeq X transition significantly advanced, surpassing year-end goals by Q3 with 78% of high-throughput gigabases and 51% of high-throughput revenue now on the X platform. Clinical customers, accounting for over 50% of the 55+ NovaSeq X placements, exhibited strong demand elasticity, with volume offsetting price in year one and revenue accelerating in year two for fully transitioned accounts. Conversely, the research market, while stabilizing, remains muted due to funding uncertainties, though pricing headwinds are easing as 91% of research volumes have transitioned to X.

Illumina is actively expanding its strategic pillars, launching new multiomics offerings like Illumina Protein Prep and a 5-base solution, and introducing the BioInsight initiative to leverage genomic data in drug discovery. Reflecting this momentum, the company raised its full-year 2025 revenue and non-GAAP EPS guidance, projecting continued clinical strength and easing research headwinds into 2026, reinforcing confidence in achieving high single-digit revenue growth and 20% non-GAAP operating margins by 2027, excluding Greater China.

Key Decisions for Investors

• Investors should continue to monitor the robust clinical market performance and the NovaSeq X transition's impact on revenue elasticity, which are key growth drivers.
• Evaluate the pace of recovery in the research and applied segments, particularly how easing pricing headwinds and improved NIH funding predictability translate into renewed spending.
• Assess the long-term potential of Illumina's multiomics expansion, including new product launches and the SomaLogic acquisition, as well as the BioInsight initiative for diversified growth.
• Consider the company's strong cash flow generation and ongoing share repurchase program as indicators of financial discipline and commitment to shareholder returns.
• Watch for further developments in the China market, as a long-term resolution to export restrictions could provide additional upside to instrument and consumables revenue.